Persistent URL of this record https://hdl.handle.net/1887/104659
In Collections
This item can be found in the following collections:
![Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial](https://scholarlypublications.universiteitleiden.nl/sites/all/themes/scholarly/img/closed_access.png)
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial
- All authors
- Lam, S.W.; Groot, S.M. de; Honkoop, A.H.; Jager, A.; Tije, A.J. ten; Bos, M.M.E.M.; Linn, S.C.; Bosch, J. van den; Kroep, J.R.; Braun, J.J.; Tinteren, H. van; E. boven; Dutch Breast Canc Res Grp BOOG
- Date
- 2014-12-31
- Journal
- European Journal of Cancer
- Volume
- 50
- Issue
- 18
- Pages
- 3077 - 3088